89 160

Cited 1 times in

COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis

Authors
 J I Shin  ;  S E Kim  ;  M H Lee  ;  M S Kim  ;  S W Lee  ;  S Park  ;  Y H Shin  ;  J W Yang  ;  J M Song  ;  S Y Moon  ;  S Y Kim  ;  Y Park  ;  D I Suh  ;  J M Yang  ;  S H Cho  ;  H Y Jin  ;  S H Hong  ;  H-H Won  ;  A Kronbichler  ;  A Koyanagi  ;  L Jacob  ;  J Hwang  ;  K Tizaoui  ;  K H Lee  ;  J H Kim  ;  D K Yon  ;  L Smith 
Citation
 EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, Vol.26(10) : 3,760-3,770, 2022-05 
Journal Title
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
ISSN
 1128-3602 
Issue Date
2022-05
MeSH
Antirheumatic Agents* / therapeutic use ; Autoimmune Diseases* ; COVID-19* / drug therapy ; Humans ; Incidence ; Rheumatic Diseases* / drug therapy ; Rheumatic Diseases* / epidemiology
Abstract
Objective: This meta-analysis aims to assess the susceptibility to and clinical outcomes of COVID-19 in autoimmune inflammatory rheumatic disease (AIRD) and following AIRD drug use.

Materials and methods: We included observational and case-controlled studies assessing susceptibility and clinical outcomes of COVID-19 in patients with AIRD as well as the clinical outcomes of COVID-19 with or without use of steroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Results: Meta-analysis including three studies showed that patients with AIRD are not more susceptible to COVID-19 compared to patients without AIRD or the general population (OR: 1.11, 95% CI: 0.58 to 2.14). Incidence of severe outcomes of COVID-19 (OR: 1.34, 95% CI: 0.76 to 2.35) and COVID-19 related death (OR: 1.21, 95% CI: 0.68 to 2.16) also did not show significant difference. The clinical outcomes of COVID-19 among AIRD patients with and without csDMARD or steroid showed that both use of steroid (OR: 1.69, 95% CI: 0.96 to 2.98) or csDMARD (OR: 1.35, 95% CI: 0.63 to 3.08) had no effect on clinical outcomes of COVID-19.

Conclusions: AIRD does not increase susceptibility to COVID-19, not affecting the clinical outcome of COVID-19. Similarly, the use of steroids or csDMARDs for AIRD does not worsen the clinical outcome.
Files in This Item:
T202203275.pdf Download
DOI
10.26355/eurrev_202205_28873
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Ji Hong(김지홍) ORCID logo https://orcid.org/0000-0001-5352-5423
Shin, Jae Il(신재일) ORCID logo https://orcid.org/0000-0003-2326-1820
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191381
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links